Abstract. The aim of the present study was to investigate the value of systemic [
Introduction

[ 18 F]fluorodeoxyglucose ([
18 F]FDG) positron emission tomography (PET)/computed tomography (CT) is a novel imaging technique that integrates functional metabolism imaging and anatomical form imaging. Imaging foci of malignant tumors is based on the increased glucose uptake of malignant tumor cells, which display morphology and sizes of foci, and, more importantly, the absence/presence and levels of activity of malignant tumor foci (1) . PET/CT has been extensively used in diagnosis of malignant tumors. Aplastic anemia (AA) is a common hematological disease characterized by bone marrow hypoproliferation and is, in certain cases, difficult to differentiate from myelodysplastic syndrome (MDS). According to the working mechanism of PET/CT, it is hypothesized that this technique is potentially useful in diagnosis of AA and differential diagnosis from MDS.
To the best of our knowledge, the function of systemic PET/CT in AA has only previously been investigated in individual cases (2) (3) (4) . No literature is available that systemically introduces characteristics of PET/CT manifestations in patients with AA and its value in the clinical setting. In the present study, characteristics of systemic PET/CT of 24 patients with AA were compared with those of healthy individuals and patients with acute leukemia (AL) or MDS to investigate the value of systemic PET/CT in diagnosis and differential diagnosis of AA and reveal its functionin indicating treatment responses when the T/B cell ratio was taken into account.
Patients and methods
Study population. In total, 24 patients were included who had been diagnosed with AA and undergone systemic PET/CT examination in The First Affiliated Hospital of Sun Yat-Sen University between May 2011 and August 2014. All patients were diagnosed according to the 2009 British guidelines for the diagnosis and management of AA (5) . Of these patients, 17 presented with severe aplastic anemia (SAA) and the other 7 presented with chronic aplastic anemia (CAA). The general features of the 24 patients with AA at the onset of the disease are presented in (6) . Of the 6 patients with AL, 4 presented with acute myelocytic leukemia and 2 presented with acute lymphoblastic leukemia; of the 4 patients with MDS, 1 presented with MDS-refractory anemia with excess blasts (RAEB) type I, 1 presented with MDS-RAEB type II and the other 2 presented with MDS-refractory cytopenia with multilineage dysplasia. Of the 16 healthy individuals, 11 were male and 5 were female. The present study was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sen University, and study participants provided written informed consent.
Therapeutic regimens and follow-up. Of the 7 patients with CAA, 1 discontinued treatment, and the other 6 received ciclosporin A (CsA) treatment; of the 17 patients with SAA, 5 discontinued treatment, 5 underwent allogeneic hematopoetic stem cell transplantation (allogeneic bone marrow transplantation from a human leucocyte antigen-identical sibling donor), 3 received antithymocyte globulin (ATG) sequential CsA treatment and 4 accepted only CsA treatment. The 2009 British guidelines for the diagnosis and management of AA (5) were used as the reference. The responses of patients were evaluated following treatment for 6 weeks. The response rate was the sum of complete remission (CR) rate and partial remission (PR) rate.
Methods. Prior to examination, all patients fasted for >6 h. Following intravenous injection of [ 18 F]FDG, patients rested in the supine position for between 50 and 60 min in a quiet and warm indoor environment. Following complete evacuation of urine, with each patient lying in the supine position on the examination bed, spiral CT scanning was first performed from the roof of the skull to the upper end of the femoral bone, prior to performing systemic 2D PET section imaging. The cross-sectional image underwent attenuation correction using the CT cross-sectional image at the same layer as emission imaging; PET image reconstruction was performed by ordered subset expectation maximization iterative reconstruction method. The reconstructed image and the CT image were fused to obtain coronal, sagittal, cross-sectional CT, PET and PET/CT images, respectively. Two nuclear medicine physicians, who were blinded to the clinical disease of the patients, analyzed the patient images and, using semi-quantitative analysis, selected all parts with hypermetabolism and sketched the region of interest for the workstation to automatically generate the maximum standardized uptake values (SUV max Fig. 1A and B) . 
Characteristics of systemic PET/CT manifestations of patients with AA Bone marrow PET/CT manifestations of patients with AA.
Bone marrow PET/CT manifestations of patients with AA were classified into the following three types (Table II) : Hypometabolism complicated by focal hyperproliferation ( Fig. 2A and B) , hypometabolism ( Fig. 2C and D) and normal bone marrow metabolism ( Fig. 2E and F) . Of the 24 patients with AA, 1 (4.2%) presented with normal bone marrow metabolism, 9 (37.5%) presented with hypometabolism and 14 (58.3%) presented with hypometabolism complicated by focal hyperproliferation.
Differences in bone marrow PET/CT manifestations in patients
with AA. Differences in the bone marrow PET/CT manifestations of patients with different types of AA were observed. Of the 17 patients with SAA, 1 (5.9%) presented with normal bone marrow metabolism, 7 (41.2%) presented with hypometabolism and 9 (52.9%) presented with hypometabolism complicated by focal hyperproliferation; of the 7 patients with CAA, none presented with normal bone marrow metabolism, 2 (28.6%) presented with hypometabolism and 5 (71.4%) presented with hypometabolism complicated by focal hyperproliferation. Association between presence/absence of concurrent infections and PET/CT focal hyperproliferation SUV max in patients with AA. Owing to marked leukopenia and neutropenia, infections are common complications of patients with AA (5). In the present study, 8/24 patients with AA presented with concurrent infections, which affected lungs, gums and the upper respiratory tracts. In total, 3/8 patients with concurrent infections presented with bone marrow hypometabolism complicated by focal hyperproliferation (SUV max =5.70±1.92). In total, 11/16 patients without concurrent infections presented with bone marrow hypometabolism complicated by focal hyperproliferation (SUV max =3.10±0.28). A statistically significant difference was identified between the two groups (P= 0.028). Only 1/24 patients developed concurrent infections at onset of the disease (bone marrow SUV max =8.30) and thus was first administered active anti-infective therapy. Later, the patient's infection was controlled. After 1 month, the bone marrow SUV max decreased to 1.70 in systemic PET/CT re-examination.
Association between bone marrow SUV max and the T/B cell ratio. All of the 24 patients with AA underwent bone marrow flow cytometric examination to determine the ratio between T lymphocytes and B lymphocytes (T/B ratio). High values of the T/B ratio indicate abnormal activation of T cells. Depending on the bone marrow SUV max , the patients were divided into two groups, one group with SUV max ≥3.00 and the other group with SUV max <3.00. T/B ratios of the two groups were calculated. The T/B cell ratios of the group with SUV max ≥3.00 and the group with SUV max <3.00 were 3.37 (2.49-6.39) and 8.74 (7.22-13.96), respectively; the difference between the two groups was statistically significant (P=0.014).
Association between the degree of bone marrow proliferation and [
18 F]FDG uptake activity in PET/CT. Each of the 24 patients with AA underwent iliac bone marrow smear examination at least twice, ilial bone biopsy once and sternal bone marrow smear examination once. It was identified that the PET/CT metabolic activity was positively correlated with the degree of proliferation at this part (including ilial bones and breast bones) (P<0.001), with Pearson's correlation coefficient, R, of 0.572. Therefore, metabolic activity shown in PET/CT may indicate, to a certain extent, the degree of bone marrow proliferation. PET, positron emission tomography; CT, computed tomography; AA, aplastic anemia; SAA, severe AA; CAA, chronic AA.
Characteristics of systemic PET/CT manifestations of patients with AL and MDS
females, whose median age was 53 years (range, 18-75 years). Systemic PET/CT of all 6 patients revealed diffuse hypermetabolism in the axial skeleton and limb bones (Fig. 3) , and the SUV max were between 2.50 and 5.60. In total, 2 patients presented with spleen enlargement and active metabolism, and the spleen SUV max were 2.30 and 3.60, respectively.
Characteristics of systemic PET/CT manifestations of patients with MDS.
The 4 patients with MDS included 2 males and 2 females, whose median age was 58.7 years (49-69 years). In total, 1 patient presented with generalized hypometabolism complicated by focal hypermetabolism (breast bones) ( Fig. 4A and B) ; 3/4 patients presented with diffuse and uniform hypermetabolism in the axial skeleton and limb bones ( Fig. 4C and D) , and the SUV max were between 2.60 and 8.50. In total, 1/4 patients with MDS presented with mild spleen enlargement; spleens of the other 3 patients were the normal size. Table III , the differences between bone marrow SUV of patients with AA and healthy individuals or patients with AL or MDS were all statistically significant (P<0.01), indicating that the overall bone marrow metabolism of patients with AA was low. Spleen SUV of patients with MDS and patients with AL were higher compared with those of patients with AA, and the differences were statistically significant (P=0.020 and 0.026, respectively). No statistically significant difference was identified in liver and mediastinal blood pool SUV between patients with AA and healthy individuals, patients with AL or patients with MDS (P>0.05). AA association between patient treatment responses and PET/CT. Of the 24 patients with AA, 6 discontinued treatment.
Comparison of overall bone marrow and extramedullar SUV of patients with AA and healthy individuals or patients with AL or MDS. As presented in
Treatment responses of the other 18 patients are presented in Table IV . Of the 6 patients with CAA treated with CsA, CAA, chronic aplastic anemia; SAA, severe aplastic anemia; PET/CT, positron emission tomography/computed tomography; SUV max , maximum standardized uptake values; T/B cell ratio, ratio between T lymphocytes and B lymphocytes; CsA, ciclosporin A; Allo-BMT, allogeneic bone marrow transplantation from a human leucocyte antigen-identical sibling donor; CR, complete remission; PR, partial remission; NC, no change. 5 responded and the other did not. Bone marrow of the non-responder presented with hypometabolism was complicated by focal hyperproliferation, the SUV max was 2.90, and the T/B cell ratio was 2.22. Of the 4 patients with SAA treated with CsA, 2 responded and the other 2 did not. SUV max of both respondents were not high, and the T/B cell ratios were also lower compared with those of the 2 non-respondents; of the 2 non-respondents, SUV max were high, and the T/B cell ratios were also significantly higher. All 3 patients treated with ATG responded.
Discussion
The results of present study have suggested that systemic PET/CT of patients with AA has specific manifestations, and may assist in differentiating from atypical MDS and, with the T/B cell ratio taken into account, may predict treatment responses.
Systemic PET/CT has been increasingly used in diagnosis and treatment of tumor patients. [
18 F]FDG is a glucose analog identical with glucose in terms of the approach and method of entering cells. The quantity of glucose transporters on the surface of tumor cells has increased, so the glucose metabolic rate of tumor cells is high. However, [
18 F]FDG is not a tumor-specific tracer. In certain benign lesions, infections, inflammatory reactions or diseased parts with markedly active proliferation, glucose uptake and metabolism are also enhanced (8, 9) , manifesting as increased SUV max in PET/CT.
The results of the present study indicate that systemic PET/CT manifestations of patients with AA may be classified into three types: Hypometabolism complicated by focal hyperproliferation, hypometabolism and normal bone marrow metabolism. In SAA or CAA, the most common systemic PET/CT manifestation is hypometabolism complicated by focal hyperproliferation, followed by hypometabolism, and the most common parts with focal hypermetabolism are the vertebral body, chest bones and ilial bones. Cicone et al (2) reported focal hypermetabolism in PET/CT of a patient with AA, whose SUV max was 2.80 and in whom focal hypermetabolism was primarily identified in the vertebral body, and these results were essentially consistent with those of the present study. The results of the present study also indicated that the metabolic activity identified using PET/CT is positively correlated with the degree of bone marrow proliferation at the corresponding part. According to the working mechanism of PET/CT, it is considered that the increase in SUV max is associated with active focal bone marrow-compensated proliferation and increased glucose uptake in bone marrow cells, so metabolic activity shown in PET/CT may indicate, to a certain extent, the degree of bone marrow proliferation (10) (11) (12) . Additionally, systemic PET/CT may reveal the metabolic activity of bone marrow of the whole body and thus may more comprehensively reflect the situation of bone marrow proliferation compared with bone marrow aspiration or biopsy of individual parts.
Infections are common complications of patients with AA (5). SUV max of parts with focal hypermetabolism of patients with AA with concurrent infections were higher compared with those of patients with AA without infections, indicating that infection is another factor that influences SUV max .
According to previously published studies, the pathogenesis of AA involves inherent defects in hematopoietic stem cells, supportive function defects of hematopoietic microenvironments and immune function disorders; in particular, abnormal T lymphocyte immunity serves an important function in development and progression of AA (13) . Peripheral blood and bone marrow T lymphocytes of patients are abnormally activated, producing soluble cytokines to inhibit hematopoiesis. In the present study, the association between the T/B cell ratio and the SUV max of bone marrow has been preliminarily investigated. The results indicate that bone marrow SUV max of patients with high T/B cell ratios are also high; an abnormal increase in the T/B cell ratio reflects, to a certain extent, abnormal activation of T cells. Therefore, bone marrow SUV max of patients with AA indicate compensated proliferation of bone marrow and reflect abnormal activation of T cells.
Differences between overall bone marrow SUV of patients with AA and healthy individuals, patients with AL and patients with MDS were statistically significant; however, bone marrow metabolism of patients with AA has decreased overall. In the clinic, it is occasionally difficult to differentiate AA with atypical manifestations from MDS (5) . In the present study, diffuse bone marrow hypermetabolism was not identified using systemic PET/CT of any patient with AA, but was identified in 75% of patients with MDS. Additionally, patients with MDS presented with more active spleen metabolism compared with patients with AA. These two points may be considered for differential diagnosis of AA and MDS. According to the working mechanism of PET/CT, enhanced spleen metabolism of patients with MDS, as indicated by increased SUV, is ascribed to the marked increased glucose metabolism in tumor cells that are disseminated with blood to the spleen. Whereas in the pathogenesis of AA, inherent defects of hematopoietic stem cells and supportive function defects of hematopoietic microenvironments are independent of the spleen, and immune function disorders primarily originate from abnormal activation of T cells, T cells are primarily lymphocytes occurring and maturing in the thymus gland, so spleen SUV of patients with AA are not high.
In regard to the association between systemic PET/CT manifestations and treatment responses of patients with AA, the results of the present study reveal that, in patients with CAA, if neither the SUV max in PET/CT nor the T/B cell ratio is high, it potentially indicates poorly compensated bone marrow metabolism and unapparent abnormal activation of T cells, and the immunosuppressant CsA may not respond well in patients with SAA; if the SUV max and the T/B cell ratio have increased, it potentially indicates marked abnormal activation of T cells, and using CsA alone will be insufficient to control immune disorders and more potent immunosuppressants, e.g. antilymphocyte globulin or ATG, have to be administered for an improved response.
For the first time, to the best of our knowledge, the present study has systematically expounded the characteristics of systemic PET/CT manifestations of patients with AA. It is concluded that PET/CT may assist in differential diagnosis of clinically atypical AA and MDS, and the T/B cell ratio may predict treatment efficacy.
